Last reviewed · How we verify
NCT05620823: STOP-HS1
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
Phase 3 trial testing Povorcitinib in Hidradenitis Suppurativa (HS) in 608 participants. Completed in 23 December 2025.
3 February 2025
Quick facts
| Lead sponsor | Incyte Corporation |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 608 |
| Start date | 19 December 2022 |
| Primary completion | 3 February 2025 |
| Estimated completion | 23 December 2025 |
| Sites | 104 locations across France, Japan, Netherlands, Greece, Belgium, Austria, Germany, Poland |
Drugs / interventions tested
- Povorcitinib — full drug profile →
- Placebo
Conditions studied
- Hidradenitis Suppurativa (HS) — all drugs for Hidradenitis Suppurativa (HS) →
Sponsor
Incyte Corporation — full company profile →
Who can join
18 and older, any sex, with Hidradenitis Suppurativa (HS). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo controlled period, followed by a 42-week extension period.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Current Clinical Trial Landscape for Hidradenitis Suppurativa: A Narrative Review.
Hunt A, Qian V, Olds H, Daveluy S. · · 2023 · cited 10× · PMID 37261652 · DOI 10.1007/s13555-023-00935-x -
Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies.
Fragoso NM, Masson R, Gillenwater TJ, Shi VY, et al · · 2023 · cited 9× · PMID 37402031 · DOI 10.1007/s13555-023-00956-6 -
Dual Targeted Therapy for Hidradenitis Suppurativa: A Narrative Review.
Kherallah K, Chung CS, Ghanshani R, Charrow A, et al · · 2026 · PMID 41276757 · DOI 10.1007/s13555-025-01601-0 -
Towards a Paradigm Shift in Delivering Hidradenitis Suppurativa Care: a Narrative Review.
Bechara FG, Marzano AV, Martorell A, van der Zee HH, et al · · 2025 · PMID 40583084 · DOI 10.1007/s13555-025-01462-7
Verify or expand the search:
- PubMed search for NCT05620823
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Povorcitinib
Trials testing the same drug.
- NCT07213973 — Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis S · Phase 2 · recruiting
- NCT06516952 — A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) · Phase 3 · recruiting
- NCT06516965 — A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) · Phase 3 · active not recruiting
- NCT06505265 — A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healt · Phase 1 · completed
- NCT06441318 — A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants · Phase 1 · completed
Other recruiting trials for Hidradenitis Suppurativa (HS)
Currently open trials in the same condition.
- NCT07213973 — Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis S · Phase 2 · recruiting
- NCT07287644 — A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa · Phase 2, PHASE3 · recruiting
- NCT07155239 — 1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa) · Phase 1 · recruiting
- NCT07021495 — SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) · recruiting
- NCT07109765 — Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa · recruiting
Other Incyte Corporation trials
Trials by the same sponsor.
- NCT07124078 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di · Phase 2 · recruiting
- NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
- NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
- NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
- NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05620823 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Incyte Corporation
- Last refreshed: 10 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05620823.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing